Lexotan (Bromazepam)

Bromazepam binds to a specific site on the GABA‑A receptor, acting as a positive allosteric modulator. This increases the receptor’s response to the neurotransmitter GABA, leading to enhanced chloride influx, neuronal inhibition, and the resulting calming, sedative, and muscle‑relaxant effects.

The appropriate dose of Lexotan is determined individually by the prescribing clinician based on the patient’s condition, age, and response to therapy. Dosage adjustments may be needed for elderly patients or those with hepatic impairment, and the prescriber will provide specific instructions.

Bromazepam is classified as a pregnancy‑category medication only after risk‑benefit assessment by a healthcare professional. It can cross the placenta and may be excreted in breast milk, so use during pregnancy or lactation should only occur when clearly needed and under medical supervision.

To request Lexotan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lexotan (bromazepam) belongs to the benzodiazepine class, offering rapid anxiolytic and sedative effects. Compared with non‑benzodiazepine anxiolytics such as buspirone, bromazepam generally has a quicker onset but may carry higher risks of dependence and withdrawal, requiring careful short‑term use.

Lexotan should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Lexotan is taken orally, usually as a tablet, with or without food as directed by the prescriber. Swallow the tablet whole with a glass of water and follow the dosing schedule provided by the healthcare professional.

Serious risks include respiratory depression, especially when combined with other central nervous system depressants, severe allergic reactions, profound sedation, paradoxical agitation, and the potential for dependence or withdrawal after prolonged use. Any sudden changes in breathing, mood, or allergic symptoms should prompt immediate medical attention.

Lexotan is contraindicated in patients with known hypersensitivity to bromazepam or other benzodiazepines, those with severe respiratory insufficiency, acute narrow‑angle glaucoma, and individuals who are currently abusing alcohol or other depressants. Caution is also advised for patients with severe hepatic impairment.